Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer (NSCLC) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The non-small cell lung cancer...
-
Smart Sensors Market Size, Share, Revenue Trends & Segmentation Analysis, By Sensor Type, Technology Type, Component, End Use, And Region | Forecast 2035
-
Strengthening revenue trajectory — Robotaxi revenues rose by 160% year-over-year in Q4, with fare-charging revenues surging by over 500%.Accelerating fleet and geographic expansion — Robotaxi scaling...
-
BEIJING, March 25, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual...
-
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call...
-
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
-
SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...
-
Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for hard-to-treat tumors CLIO-8221 is the first program from...
-
Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren,...
-
Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates,...